Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Alvotech (NASDAQ: ALVO) tekur þátt í 23. árlegu heilbrigðisráðstefnu fjárfestingabankans Morgan Stanley, sem haldin verður dagana 8.-10. september nk., í New York. Fundir með fjárfestum verða haldnir...
-
REYKJAVIK, Iceland, June 4, 2025 - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its...
-
Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration...
-
Lyfið verður markaðssett í Evrópu undir heitinu Mynzepli og verður notað til meðferðar við augnbotnahrörnun og fleiri augnsjúkdómumMilljónir Evrópubúa þurfa að takast á við áhrif...
-
Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration...
-
REYKJAVIK, ISLAND (20 augusti 2025) — Alvotech (NASDAQ: ALVO), ett globalt bioteknikföretag som specialiserat sig på utveckling och tillverkning av biosimilarer för patienter över hela världen,...
-
REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced...
-
Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flows Continued expansion of...
-
Yfir 200% aukning á tekjum af sölu lyfja á fyrri helmingi ársins miðað við sama tíma í fyrraAnnar ársfjórðungur sá besti í sögu félagsins hvað varðar handbært fé frá rekstri Nýir samningar um...
-
Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flowsContinued expansion of commercial partnerships for...